Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer

BMC Cancer
Se Jun Park1, Ju Yeon Park2, Kabsoo Shin1, Tae Ho Hong3, Myung Ah Lee1, Younghoon Kim4, In-Ho Kim1
1Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, 222 Banpo-daero, Secho-gu, Seoul, Korea
2Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of General Surgery, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea
4Department of Pathology, The Catholic University of Korea, Seoul St. Mary’s Hospital, College of Medicine, Seoul, Korea

Tóm tắt

Abstract Background Interactions between the programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) lead to immune evasion in various tumors and are associated with poor prognosis in patients with pancreatic cancer; however, the roles of PD-L1-containing exosomes in pancreatic cancer is poorly understood. Here, we investigated the correlation between circulating exosomal PD-L1 (exoPD-L1) and PD-L1 expression in tumor tissue, and survival outcomes in patients with advanced PDAC. Methods Exosomes were derived from pre-treatment serum samples isolated using ExoQuick kit from 77 patients with advanced pancreatic cancer. Exosomal PD-L1 (exoPD-L1) was detected by enzyme-linked immunosorbent assay, and matched tumor tissues PD-L1 expression were evaluated by PD-L1 immunohistochemistry (22C3) assay, described with combined positive score. Cutoff value of exoPD-L1 for survival was assessed with receiver operating characteristic curve analysis. Kaplan-Meier analysis was performed to obtain median overall survival (OS), and hazard ratio was estimated using a stratified Cox regression model. Results The median exoPD-L1 serum concentration was 0.16 pg/mg, with undetected levels in seven patients. ExoPD-L1 levels were significantly higher in patients with systemic disease than in those with locally advanced disease (p = 0.023). There was a significantly higher proportion of elevated exoPD-L1 levels in patients with positive PD-L1 expression compared to patients with negative PD-L1 expression (p = 0.001). Patients were classified into groups with low and high exoPD-L1 levels using ROC curve-derived cutoffs (0.165 pg/mg; area under the curve, 0.617; p = 0.078). At a median follow-up of 8.39 months, the median OS was 13.2 (95% CI, 8.17–18.3) and 6.36 months (95% CI, 3.27–9.45) in the low and high exoPD-L1 groups, respectively (HR = 0.61; 95% CI, 0.35–1.04; p = 0.059). ExoPD-L1 levels did not affect the proportion of CD8+CD69+ effector cytotoxic T cells in either of the groups (p = 0.166). Conclusions The serum-derived exoPD-L1 levels were higher in metastatic pancreatic cancer than locally advanced disease. Collectively, higher serum exoPD-L1 levels in patients with advanced pancreatic cancer suggested worse survival outcomes and may have clinical implications.

Từ khóa


Tài liệu tham khảo

Siegel Rebecca L, Miller Kimberly D, Jemal, Ahmedin. Cancer Stat 2019 CA: cancer J Clin. 2019;69(1):7–34.

Hidalgo M. Pancreatic cancer.New England Journal of Medicine. 2010 Apr29;362(17):1605–17.

Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 2017 Dec;17(1):1–7.

Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, Konukiewitz B, Öllinger R, Zwiebel M, Strong A, Yen HY. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018 Feb;554(7690):62–8.

Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1/PD‐L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019 Oct;234(10):16824–37.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E. Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine. 2015 May 21;372(21):2018-28.

Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y. PD-1/PD-L1 and immunotherapy for pancreatic cancer.Cancer letters. 2017 Oct28;407:57–65.

Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, Prisco D. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother. 2013 Jul;62(7):1249–60.

Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013 Mar;108(4):914–23.

Zhao F, Obermann S, Von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology. 2009 Sep;128(1):141–9.

Hu Y, Chen W, Yan Z, Ma J, Zhu F, Huo J. Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis.Medicine.2019 Jan;98(3).

Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020 Apr;20(4):209–15.

Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go.Cell. 2016 Mar10;164(6):1226–32.

Fan Y, Che X, Qu J, Hou K, Wen T, Li Z, Li C, Wang S, Xu L, Liu Y, Qu X. Exosomal PD-L1 retains immunosuppressive activity and is associated with gastric cancer prognosis. Ann Surg Oncol. 2019 Oct;26(11):3745–55.

Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical Significance of PD-L1 + Exosomes in Plasma of Head and Neck Cancer PatientsPD-L1 + Exosomes in Plasma of HNC Patients. Clinical cancer research.2018 Feb15;24(4):896–905.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 Aug;560(7718):382–6.

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien AS, Incorvaia L, Russo A, Olive D, Iovanna J. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019 Apr 3;8(4):e1561120.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015 Jul;523(7559):177–82.

Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr protocols cell biology. 2006 Mar;30(1):3–22.

Qu JL, Qu XJ, Qu JL, Qu XJ, Zhao MF, Teng YE, Zhang Y, Hou KZ, Jiang YH, Yang XH, Liu YP. The role of cbl family of ubiquitin ligases in gastric cancer exosome-induced apoptosis of Jurkat T cells. Acta oncologica. 2009 Jan 1;48(8):1173-80.

Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis.Medicine. 2018 Jan;97(3).

Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology. 2017 May 4;6(5):e1310358.

America DN. PD-L1 IHC 22C3 pharmDx interpretation manual. 2018. 2018.

Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. 2019 Dec;18(1):1–0.

Lux A, Kahlert C, Grützmann R, Pilarsky C. c-Met and PD-L1 on circulating exosomes as diagnostic and prognostic markers for pancreatic cancer.International journal of molecular sciences. 2019 Jul5;20(13):3305.

Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D, Liu H. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J translational Med. 2019 Dec;17(1):1–0.

Guo Y, Ji X, Liu J, Fan D, Zhou Q, Chen C, Wang W, Wang G, Wang H, Yuan W, Ji Z. Effects of exosomes on pre-metastatic niche formation in tumors. Mol Cancer. 2019 Dec;18(1):1–1.

Kim DH, Kim H, Choi YJ, Kim SY, Lee JE, Sung KJ, Sung YH, Pack CG, Jung MK, Han B, Kim K. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019 Aug;51(8):1–3.

Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.International journal of cancer. 2016 Jul15;139(2):396–403.

Costantini A, Julie C, Dumenil C, Hélias-Rodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune S, Chinet T, Emile JF, Giroux Leprieur E. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018 Aug 3;7(8):e1452581.

Chang B, Huang T, Wei H, Shen L, Zhu D, He W, Chen Q, Zhang H, Li Y, Huang R, Li W. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019 Mar;68(3):353–63.

Wang X, Li X, Wei X, Jiang H, Lan C, Yang S, Wang H, Yang Y, Tian C, Xu Z, Zhang J. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal transduction and targeted therapy.2020 Apr17;5(1):1–2.

Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunological reviews. 2010 May;235(1):105–16.

Shen W, Tao GQ, Zhang Y, Cai B, Sun J, Tian ZQ. TGF-β in pancreatic cancer initiation and progression: two sides of the same coin. Cell & bioscience. 2017 Dec;7:1–7.

Dorman K, Gerckens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers. J Cancer Res Clin Oncol. 2022 Jun;23:1–2.

Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic CancerIL1β Promotes Immune Suppression in Pancreatic Cancer. Cancer research. 2020 Mar 1;80(5):1088 – 101.

Thông tin
Thông tin xuất bản

BMC Cancer

Thông tin tác giả